Best GLP-1 Platforms by Category (2026)

Part of the GLP-1 Resource Hub | By Dr. Francis Yap | Verified as of November 2026

Quick Answer

No single platform wins every category. In U.S. News’s first-ever GLP-1 telehealth ratings (August 12, 2026), Amazon One Medical scored highest (4.8) and led on insurance support, Found led on clinical support, Noom on supplemental support and Ro on customer satisfaction. If you already have a prescription and no coverage, manufacturer cash-pay programs (LillyDirect, NovoCare, via TrumpRx) are the lowest-cost branded route. Eligible Medicare enrollees can pay $50 a month through the temporary GLP-1 Bridge. Treat compounded products with caution.

1. How U.S. News rated the platforms

Most “best GLP-1 provider” lists online are affiliate or press-release rankings. The only independent, published rubric I found is U.S. News & World Report’s 2026-2027 Best GLP-1 Telehealth Platforms. Its design determines what the scores can and cannot tell you:

  • Scope: 20 platforms offering brand-name drugs (Wegovy, Zepbound, Ozempic, Foundayo), scored from 1 to 5 using 14,161 data points. Compounded-only companies were excluded, and for mixed platforms only the branded business was judged.
  • Consumer input: a survey of 1,251 U.S. adults who used a GLP-1 from an online platform in the previous 12 months (PureSpectrum, May to July 2026).
  • Weights: clinical support 25%, screening rigor 20%, transparency 17%, insurance assistance 15%, supplemental care 13%, customer satisfaction 10%.
  • Cutoff: “best” was set at the largest natural drop in the score distribution, which separated 11 platforms from the rest.

Best Weight Loss Peptides

Limitation: the scores measure access, oversight, pricing transparency and satisfaction. They are not weight-loss outcome data.

2. Best by category

Category Best option Basis
Highest overall rating Amazon One Medical (4.8) U.S. News 2026-2027
Insurance support Amazon One Medical U.S. News category award
Clinical support Found (4.6) U.S. News category award
Supplemental support (beyond the prescription) Noom (4.3) U.S. News category award
Customer satisfaction Ro (4.4) U.S. News category award
Lowest branded cash price Manufacturer programs (LillyDirect, NovoCare) via TrumpRx.gov Manufacturer-stated prices; you still need a prescriber
Medicare enrollees Medicare GLP-1 Bridge ($50 copay) CMS pilot, July 2026 to December 2027

Full U.S. News “best” list: Amazon One Medical 4.8; Found 4.6; Mochi Health 4.4; Ro 4.4; Noom 4.3; PlushCare 4.1; Fridays 4.0; Ivim Health 4.0; LifeMD 4.0; Remedy Meds 3.9; WeightWatchers 3.9. Equal displayed scores are rounded and are not true ties. Hims & Hers is not on this list; since March 2026 it has offered Novo Nordisk’s branded Ozempic and Wegovy and has largely stopped marketing compounded versions.

3. Pricing snapshot (verified as of November 11, 2026)

Product / channel Cash price per month Notes
Wegovy pill (TrumpRx / NovoCare) From $149 Starting doses; price varies by strength
Wegovy pen $199 intro, then $349 Intro covers first two fills of the two lowest strengths for new patients; offer scheduled to end December 31, 2026
Zepbound vials (LillyDirect) $299 to $449 By dose, per Lilly’s December 2025 announcement; TrumpRx lists Zepbound from $299
Foundayo (oral orforglipron) From $149 Higher doses rise toward $349; one top-dose price requires refills within 45 days. Weaker source: re-check on TrumpRx.gov
Medicare GLP-1 Bridge $50 Eligible Part D enrollees only

TrumpRx does not prescribe or ship. Ozempic and Wegovy use a pharmacy coupon; Zepbound and Foundayo route to LillyDirect. Telehealth membership or consultation fees are separate and vary by platform, so ask for the all-in monthly cost before enrolling. Check LillyDirect and TrumpRx.gov for current numbers.

Related: GLP-1 cost and coverage 2026 and Start GLP-1 weight loss in 2026.

4. Medicare and insurance

  • The Medicare GLP-1 Bridge began July 1, 2026 and is scheduled to run through December 31, 2027, giving eligible Part D enrollees obesity-indicated GLP-1s for a flat $50 copay.
  • As of June 2026 it covered Wegovy (injection and pill), the Zepbound KwikPen and Foundayo.
  • It operates outside Part D: the copay does not count toward the deductible or the $2,100 out-of-pocket cap, and Extra Help cannot be applied.
  • People already on a Part D GLP-1 for conditions such as type 2 diabetes are not eligible for the Bridge. Clinical criteria apply at the start of therapy.

For commercial plans, prior authorization and formulary rules vary. Amazon One Medical’s U.S. News win for insurance support makes it the best-documented starting point for navigating coverage.

5. Compounded GLP-1s: why they are excluded from the rankings

Compounded semaglutide and tirzepatide surged during the brand shortages and are not FDA-reviewed for safety, effectiveness or quality before marketing. In 2026 the FDA sent warning letters to 30 telehealth companies over false or misleading compounded-GLP-1 claims, and in February the agency warned Hims & Hers over a $49 compounded semaglutide pill, which the company then withdrew. On March 9, 2026 Novo Nordisk and Hims & Hers announced a partnership under which Hims offers branded Wegovy and Ozempic and stops marketing compounded alternatives except where medically necessary. If a clinician recommends a compounded product, ask which pharmacy makes it and why a branded option is not suitable. Be skeptical of “best compounded provider” rankings that omit this regulatory context.

6. Evidence and source-quality tiers

CEBM levels grade clinical evidence. Because this article compares access platforms, I apply them to drug efficacy and use an analogous source-quality grade for everything else.

Claim Tier Comment
Semaglutide 2.4 mg and tirzepatide reduce body weight substantially (roughly 15% in STEP 1; up to about 21% in SURMOUNT-1) CEBM Level 1 (RCTs) Drug effect; independent of which platform dispenses it
Platform quality ratings Tier B: independent rubric plus consumer survey No clinical outcomes; first-year ratings
Medicare Bridge terms Tier B: government pilot, reported by secondary sources Confirm at CMS.gov
Cash prices Tier C: manufacturer-stated Changes frequently; promotional offers expire
Compounding enforcement Tier B: regulator action reported by trade press Fast-moving
Vendor “best of” rankings, press releases Tier D: not used for ranking Commercial incentives

7. How to choose

  • Have commercial insurance: start with a platform strong on insurance support, and ask about prior authorization before paying membership fees.
  • Paying cash: get a prescription, then compare the manufacturer price with the platform’s all-in monthly cost.
  • On Medicare Part D: ask your clinician about Bridge eligibility first.
  • Want coaching or closer follow-up: weight clinical and supplemental support above price.
  • Red flags: no clinician review, unclear drug or pharmacy source, no stated total price, or claims that a compounded product is “the same as” a brand drug.

8. AI personalization guide

Give any assistant your state, coverage type (commercial, Medicare, none), target drug and budget. Ask it to separate branded from compounded options and to cite pricing pages with dates.

Assistant Suggested prompt
Claude “I have Medicare Part D and no diabetes. Walk me through Bridge eligibility, then list questions to ask my doctor.”
ChatGPT “Compare my all-in monthly cost for Zepbound via LillyDirect versus a telehealth platform with a $X membership fee.”
Gemini “Using today’s manufacturer pages, what is the current cash price of my dose, and when does any intro offer end?”
Perplexity “Cite the latest U.S. News GLP-1 telehealth ratings and any platform changes since August 2026.”

9. Frequently asked questions

What is the best GLP-1 telehealth platform in 2026?
There is no single best. Amazon One Medical scored highest overall (4.8) and won insurance support; Found won clinical support, Noom supplemental support and Ro customer satisfaction. Your coverage situation should drive the choice.

Does U.S. News rate compounded GLP-1 providers?
No. Compounded-only companies were excluded, and mixed platforms were judged on their branded business only.

Is TrumpRx a pharmacy or a telehealth service?
No. It lists discounted cash prices and routes you to a pharmacy coupon or the manufacturer’s program. You still need a prescription.

How much do Wegovy and Zepbound cost without insurance?
Roughly $149 a month (Wegovy pill, starting doses) to $449 (higher-dose Zepbound vials). The Wegovy pen is $349 after an introductory $199 offer scheduled to end December 31, 2026. Confirm current prices before ordering.

Does Medicare cover GLP-1s for weight loss?
Temporarily. The Medicare GLP-1 Bridge (July 1, 2026 to December 31, 2027) offers eligible Part D enrollees a $50 monthly copay, outside normal Part D cost-sharing.

Are compounded semaglutide and tirzepatide safe?
They are not FDA-reviewed before marketing, and regulators have been actively warning telehealth sellers in 2026. Discuss the pharmacy source with your clinician.

Does the platform change how much weight I lose?
Trial results come from the drug, dose and adherence. Platform ratings measure access and service, not outcomes.

Do I need a prescription for a manufacturer cash-pay program?
Yes, from a licensed clinician.

10. Sources, disclosures and update log

Disclosure: This article contains no affiliate links to any platform listed. Rankings reproduce independent U.S. News results and were not influenced by payment. This site participates in affiliate programs on other pages.

Medical disclaimer: This is general information, not medical advice. GLP-1 medications have contraindications and side effects; decisions about starting, switching or stopping should be made with a licensed clinician.

Update log: November 11, 2026, first publication. Prices and offers change frequently; re-verify before each update.

Comments

Post a Comment

Popular posts from this blog

GLP-1 Hub 2026: Approved Drugs, Pills vs Injections, Retatrutide & Safety

Image
Home › GLP-1 Hub By Dr. Frank Yap, MD  |  Last updated: November 2026  |  Purpose: evidence and safety education, not individual medical advice Quick Answer GLP-1 therapy now includes injections and, since 2025–2026, two FDA-approved pills : oral Wegovy (semaglutide 25 mg, December 2025) and Foundayo (orforglipron) , approved April 1, 2026 as the first non-peptide oral GLP-1 for weight management.  The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Retatrutide is not approved anywhere ; it remains in Phase 3 testing. Compounded and gray-market GLP-1 or peptide products are not FDA-approved, and the FDA issued warning letters to telehealth compounders in March 2026. Any GLP-1 plan should run through a licensed physician and a regu...
Read more

GLP-1 Cost and Coverage 2026: Self-Pay, Insurance and Pill Prices

Image
By Dr. Frank Yap, MD  |  Last reviewed: November 2026  |  Purpose: evidence and cost education, not individual medical or financial advice Quick Answer In November 2026, advertised US self-pay prices for weight-management GLP-1s start at $149 per month (Wegovy pill 1.5 mg, Foundayo 0.8 mg) and run to $449 for higher-dose Zepbound KwikPen, down from list prices above $1,000. The White House announced the Eli Lilly and Novo Nordisk pricing agreements on November 6, 2025 and launched TrumpRx.gov on February 5, 2026; those announcements are the policy backdrop, but your price still depends on product, dose, insurance and offer expiry (several end December 31, 2026 ). Eligible Medicare patients may pay $50 per month through the GLP-1 Bridge (July 1, 2026 to December 31, 2027). This guide covers prescription GLP-1 and related weight-management medications in the United States. Prices are ...
Read more

GLP-1 for Knee Osteoarthritis: Pain Relief, Weight Loss, PRP, Stem Cells or Surgery?

Image
Updated November 2026 | By the OneDayMD Research Team | Reviewed by Dr Frank Yap, MD Can GLP-1 medications such as semaglutide help people with knee osteoarthritis avoid injections or knee replacement? The answer is more encouraging than it was a few years ago, but important uncertainties remain. A major randomized trial published in the New England Journal of Medicine found that semaglutide improved both body weight and knee osteoarthritis symptoms in people with obesity. In September 2026, the American College of Rheumatology (ACR) added a conditional recommendation for GLP-1 receptor agonists to help people with knee osteoarthritis and obesity achieve an appropriate weight, alongside diet and exercise. However, losing weight, relieving pain, regenerating damaged cartilage and avoiding surgery are different outcomes. Evidence supporting one does not automatically prove the others. This guide compares GLP-1 medications with platelet-rich plasma (PRP), stem-cell injectio...
Read more

Ozempic Pill vs Wegovy Pill vs Foundayo: Comparison, Price and Side Effects (2026)

Image
Last updated: November 2026  |  By: One Day Advisor Editorial Team Which oral GLP-1 is for diabetes, which is for weight loss, what each costs, and who is winning the oral obesity market Quick Answer The Ozempic pill and the Wegovy pill are both oral semaglutide from Novo Nordisk, but only the Wegovy pill is approved for weight loss. The Ozempic pill is approved for type 2 diabetes and cardiovascular risk reduction in adults with type 2 diabetes. Foundayo (Eli Lilly’s orforglipron) is a different, non-peptide drug approved for weight management. Self-pay prices start at $149 per month for all three. In weight-loss prescriptions the Wegovy pill leads Foundayo about 2.9 to 1 (about 183,000 vs 63,110 weekly scripts, week ended October 23, 2026). Foundayo needs no fasting or water rules; the two semaglutide pills do. Jump to Ozemp...
Read more

GLP-1 and Beyond: What the Evidence Shows on Brain Health, Cancer Risk, Addiction, Knee Osteoarthritis and Next-Generation Drugs (2026)

Image
Quick Answer This article examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyond classic metabolic disease—especially the brain—while highlighting the shift toward multi-receptor agents. Observational data link these drugs to lower dementia risk in some metabolic populations, but large Alzheimer’s trials (EVOKE/EVOKE+) have not shown clinical benefit. Cancer-risk reductions appear largely tied to weight loss and related changes rather than proven intrinsic anticancer activity. Addiction research is promising but early. Key limitations include gastrointestinal effects, muscle loss, variable response, and weight regain after stopping. The issue stresses the need for better mechanistic studies, rigorous trials, and broader access strategies. What the Science GLP-1 Special Issue Covers The 5 November 2026 Science special issue (“GLP-1 and Beyond”) examines how GLP-1 receptor agonists and related metabolism-targeting drugs affect systems beyon...
Read more

Peptide Therapy in 2026: What the Evidence Says About BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon

Image
Updated:  November 2026 | Editorial team: OneDayMD | Purpose: Evidence and safety education Peptides are increasingly promoted for faster injury recovery, muscle growth, fat loss, better skin, improved sexual function, sleep and “anti-aging.” Some peptide medicines have transformed modern care. Others are experimental compounds with promising laboratory findings but little reliable evidence in people. The word peptide describes a type of molecule. It is not a guarantee of safety, effectiveness, purity or regulatory approval. Insulin and semaglutide are peptides; so are unapproved compounds sold online as “research chemicals.” Their evidence, manufacturing standards and medical uses are not interchangeable. Key takeaways Approved peptide medicines are not the same as research peptides. Approved medicines have been evaluated for specific uses, doses and risks. BPC-157, TB-500, MOTS-c, KPV, Semax and Epitalon remain inves...
Read more

GLP-1 Manual 2026: The Complete Guide to GLP-1 Drugs, Benefits, Risks, Dosing, Muscle Loss & Long-Term Strategy

Image
Updated November 2026 GLP-1 therapy has moved far beyond the simple phrase “weight-loss drugs.” Semaglutide, tirzepatide and newer oral and multi-receptor therapies are reshaping obesity, diabetes and cardiometabolic care. But a useful GLP-1 guide needs two columns: what these medicines can do, and what they can cost if treatment is poorly matched, escalated too quickly, or accompanied by inadequate nutrition and physical activity. This GLP-1 manual brings the major evidence together in one place: the drug family, approved 2026 therapies, emerging candidates, expected weight loss, cardiovascular and kidney outcomes, liver and sleep-apnea data, adverse effects, contraindications, oral contraceptive issues, peri-procedural considerations, muscle and bone preservation, monitoring and what happens when treatment is stopped. The central idea: GLP-1 therapy should not be judged by the scale alone. The clinically meaningful goal is better health wit...
Read more

How to Prevent Muscle Loss on GLP-1 Drugs: Protein, Resistance Training & Body Composition Guide (2026)

Image
Home › GLP-1 Hub > GLP-1 Muscle Loss By Dr. Frank Yap, MD  |  Last updated: October 2026  |  Purpose: evidence and safety education, not individual medical advice GLP-1-based medicines have changed the treatment of obesity by making substantial, sustained weight loss possible for many people. But as the scale goes down, an important question follows: How much of the weight being lost is fat, and how much is lean tissue? This matters because long-term health is not determined by body weight alone. Preserving skeletal muscle, strength, physical function and nutritional adequacy is particularly important during substantial weight loss. The good news is that current evidence does not support the idea that GLP-1 therapies simply “eat away” muscle. Most weight lost with semaglutide and tirzepatide is fat mass. At the same time, measurable reductions in lean mass can occur, particularly during large or rapid weight loss. The ...
Read more

GLP-1 Clinical Trials & Research Tracker 2026

Semaglutide, tirzepatide, retatrutide, CagriSema, orforglipron and next-generation obesity medicines Research snapshot: 3 November 2026 · Curated Phase 3, pivotal and landmark human studies · Last editorial review: 3 November 2026 This tracker follows major clinical studies of GLP-1 receptor agonists and related incretin-based medicines across obesity, type 2 diabetes, cardiovascular disease, kidney disease, metabolic dysfunction-associated steatohepatitis (MASH), obstructive sleep apnea and other obesity-related complications. It is designed as a research navigation tool: each entry links to its ClinicalTrials.gov record and, where available, a peer-reviewed paper, regulatory source or clearly identified sponsor announcement. The tracker distinguishes completed trials from posted results and distinguishes peer-reviewed evidence from sponsor-reported topline findings. How to use this tracker: Search by medicine, trial acronym, NCT number or condition. Use the dropdowns...
Read more

Start GLP-1 Correctly

Use GLP-1 correctly, with the evidence in front of you Independent, physician-written guides to semaglutide, tirzepatide and the new oral options. Choose a medicine to ask about, plan the cost, and track your progress privately. Compare your options Open the free tracker Sourced to U.S. FDA labeling. Every claim carries a CEBM evidence tier. We never recommend a dose. Quick Answer GLP-1 Advisor is an evidence-based guide to GLP-1 weight-management medicines. Start with the comparison guide, check cost and coverage, then use the free tracker once treatment begins. Your prescriber sets your dose. Where are you in your GLP-1 journey? Stage 1: Considering Which options should I ask about? Wegovy, Zepbound, and the daily pills, compared by goal, route and tolerability. Start GLP-1 weight loss in 2026 Pill or weekly injection? Stage 2: Starting What will it cost and who prescribes it? Prices, insurance coverage and ways to see a doctor. GLP-1 cost and coverage 2...
Read more